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ABSTRACT
Background. An outcome assessment was performed of
patients with unresectable colorectal liver metastases
(CRLM) treated in second or third line with floxuridine
(FUDR)-based hepatic artery infusion (HAI).
Methods. Twenty-three patients who were pretreated with
systemic (immuno)chemotherapy received FUDR-HAI
alone or combined with systemic chemotherapy. We
reviewed patient charts and our prospective patient data-
base for survival and associated risk factors.
Results. Patients received FUDR-HAI for unresectable
CRLM from January 2000 to September 2010. Twelve
patients (52%) received concurrent systemic chemother-
apy. Median overall survival (OS), progression-free
survival (PFS), and hepatic PFS were 15.6 months (range,
2.5–55.7 months), 3.9 months (range, 0.7–55.7 months),
and 5.5 months (range, 1.6–55.7 months), respectively.
The liver resection rate after HAI was 35%. PFS was better
in patients undergoing secondary resection than in patients
without resection (hazard ratio [HR] 0.21; 95% confidence
interval [95% CI] 0.07–0.66; P = 0.0034), while OS
showed a trend toward improvement (HR 0.4; 95% CI
0.13–1.2; P = 0.09). No differences were observed in OS
(P = 0.69) or PFS (P = 0.086) in patients who received
FUDR-HAI alone compared with patients treated with
combined regional and systemic chemotherapy. No statis-
tically significant differences were seen in patients
previously treated with one chemotherapy line compared
with patients treated with two lines. Presence of extrahe-
patic disease was a negative risk factor for PFS (liver-only
disease: HR 0.03; 95% CI 0.0032–0.28; P \ 0.0001).
Toxicities were manageable with dose modifications and
supportive measures.
Conclusions. FUDR-HAI improves PFS and results in a
trend toward improved OS in selected patients able to
undergo liver resection after tumor is downsized.
Colorectal carcinoma is the fourth most frequent cause
of cancer mortality worldwide.1 At diagnosis, 25% of all
colorectal cancer patients have distant (synchronous)
metastases, and another 30% develop metastatic disease
later in their disease course. In cases of a relapse after
resection of the primary tumor (metachronous metastases),
the liver is the only affected organ in 50% of the patients.2
Chemotherapy by hepatic artery infusion (HAI) has
been applied for more than 50 years with the rationale to
increase the exposure of liver tumors to cytotoxic drugs by
direct application through the hepatic artery.3,4 The drug
most commonly used for intra-arterial application is flox-
uridine (FUDR), an active metabolite of 5-fluorouracil. The
advantage of FUDR is a rapid first-pass effect in the liver
with limited systemic toxicity.5 HAI has been used to
downsize unresectable colorectal liver metastases (CRLM)
as well as in the adjuvant setting after resection of
CRLM.6–15 We have previously reported encouraging data
by combining HAI with portal vein ligation in an attempt to
downsize unresectable CRLM, demonstrating a response
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rate of 58% (6 of 11 patients) and a resection rate of 38%
(4 of 11 patients).16
When HAI was introduced on a routine basis in a few
centers, effective systemic chemotherapy was not available
for the treatment of colorectal cancer. Recent advances in
the systemic treatment of colorectal cancer using combi-
nations of chemotherapeutic and biological agents as first-
line therapy in nonresectable CRLM showed impressive
response rates of up to 68% and resection rates of up to
38%.17–20 However, studies comparing HAI with systemic
immunochemotherapy are missing, and thus the current
role of regional chemotherapy as first-, second-, or third-
line treatment has not yet been clarified. A recently pub-
lished meta-analysis comparing HAI with systemic
chemotherapy failed to identify differences between the
two treatment strategies, mostly because HAI was only
assessed as a sole treatment and not considered in combi-
nation with systemic chemotherapy.21,22
Experience with HAI at our institution began 10 years
ago, which was used either as a sole treatment or, more
recently, in combination with systemic chemotherapy. HAI
was mainly used as a second- or third-line downsizing
strategy in nonresectable CRLM. The aim of the present
study was to report on the survival of our CRLM patients
treated with FUDR-HAI alone or combined with systemic
chemotherapy, as well as to identify risk factors prognostic
for survival.
METHODS
We retrospectively analyzed patients with unresectable
CRLM who were treated with FUDR-HAI after implantation
of a subcutaneous HAI pump at our hepato-pancreato-biliary
center based on a prospective database including all surgical
and medical procedures. All patients analyzed had been pre-
treated with systemic chemotherapy or systemic immunoche-
motherapy for advanced disease. Adjuvant chemotherapy
was considered a previous treatment line only if applied
within 12 months before onset of FUDR-HAI.
The primary endpoint of this analysis was survival
(overall survival [OS], progression-free survival [PFS], and
hepatic PFS). Secondary endpoints were treatment efficacy
(response rates and resectability), prognostic factors,
adverse events, and surgical complications.
Response was assessed on imaging data available by
means of the Response Evaluation Criteria in Solid Tumors.
In patients without available imaging data, response was
assessed by analyzing the radiographic reports or the entries
of the attending physicians in the patient charts.
Surgical complications were documented according to a
treatment-oriented complication score.23 Adverse events
were coded as documented in the patient charts according
to the NCI Common Terminology Criteria for Adverse Events
v3.0 (http://ctep.info.nih.gov/reporting/ctc_v30.html).
Two different catheter systems were used for HAI
therapy: an Arrow 3000-30 (Codman 3000; Johnson and
Johnson, Raynham, MA), and a Medtronic IsoMed Con-
stant Flow Pump (Medtronic, Minneapolis, MN). The
treatment strategy for every patient with CRLM was dis-
cussed and determined at a multidisciplinary board meeting
of our Swiss hepato-pancreato-biliary center attended by
surgeons, medical and radiation oncologists, radiologists,
and gastroenterologists. HAI was predominantly consid-
ered in fit patients with nonresectable CRLM.
Resectability was assessed according to a modern
aggressive approach depending on macroscopic complete
resectability of all lesions providing sufficient remnant
liver tissue.24,25 In case of imminent R2 resection, addi-
tional ablative treatment was performed intraoperatively
(cryoablation or radiofrequency ablation) to treat all
CRLM. Limited but resectable extrahepatic disease was not
considered to be a contraindication for pump implantation.
All patients provided written informed consent for sci-
entific evaluation of their data before implantation of the
pump system. The analysis was approved by our local
ethics committee.
Operative Technique
Laparotomy was performed by a right subcostal inci-
sion. All patients underwent cholecystectomy to avoid
chemical cholecystitis. The implantation of the arterial
catheter was subsequently performed by the Watkins
technique.26 After careful preparation of the common
hepatic artery and ligature of the right gastric artery, the
gastroduodenal artery was identified and ligated 1.5 cm
distal its runoff from the hepatic artery. The catheter was
inserted into the gastroduodenal artery and advanced to the
junction of the common hepatic and gastroduodenal arter-
ies without extending into the lumen of the hepatic artery.
The catheter was fixed by bidirectional ligation on either
side of its cuff. Fluorescein was injected into the catheter to
indicate its exact position and to exclude misperfusion. The
correct liver perfusion was proven by the Wood’s lamp.
The infusion pump was implanted into a subcutaneous
pocket in the right lower abdominal wall. In the case of an
additional left hepatic artery, the nondominant left artery
was ligated because intrahepatic shunts rapidly reconstitute
and provide sufficient blood supply to the liver within a
few days.27 An aberrant or replaced right hepatic artery
was considered to be a contraindication for catheter
implantation and HAI.
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Treatment Regimens
FUDR-HAI was administered every 28 days as a 14-day
infusion at 0.12 mg/kg 9 30 divided by flow rate. Dexa-
methasone 20 mg and heparin 30,000 IU were added and
the pump volume completed with normal saline. On day 15
of every cycle, the pump reservoir was emptied and refilled
with dexamethasone 20 mg, heparin 30,000 IU, and nor-
mal saline.
Additional systemic chemotherapy consisted of a
FOLFOX-like regimen with oxaliplatin 100 mg/m2 on day
1, leucovorin 400 mg/m2 on day 1, and 5-fluorouracil
1200 mg/m2 over 46 h. One patient received a combination
of oxaliplatin 100 mg/m2 on day 1 and irinotecan 150 mg/m2
on day 1. Concurrent systemic chemotherapy was adminis-
tered every 2 weeks. FUDR dose and systemic chemotherapy
dose were adapted in cases of hematologic or nonhemato-
logic toxicity. In addition, a strict dose adjustment algorithm
was used to modify FUDR dosing depending on liver func-
tion tests during every cycle.28 All patients had follow-up
including laboratory assessment at least every 2 weeks.
Imaging by computed tomographic scan, positron emission
tomography–computed tomography, and/or magnetic reso-
nance imaging was usually performed every 2 to 3 months.
Statistical Analysis
Descriptive statistics are presented in the form of
medians (range) for continuous variables and counts (per-
centage) for all categorical variables. Survival estimates
were computed by the method of Kaplan and Meier.29 Cox
proportional hazard regression was used to estimate uni-
variate hazard ratios and to test the statistical significance
of risk factors for survival.30 Only P values of\0.01 were
considered statistically significant as a result of the small




From January 2000 to September 2010, a total of 23
patients with unresectable CRLM received FUDR-HAI and
were eligible for the final analysis. All patients had bilobar
disease, and 19 patients (83%) had more than four CRLM.
Patients had previously received either one (n = 17; 74%)
or two (n = 6; 26%) lines of systemic chemotherapy.
Eleven patients (48%) had received irinotecan-based
combination chemotherapy, and 12 patients (52%) had
received oxaliplatin-based combination chemotherapy.
Other lines were 5-fluorouracil monotherapy (n = 4; 17%)
and raltitrexed monotherapy (n = 1; 4%). Eight patients
(35%) had also received additional immunotherapy com-
bined with their chemotherapy. Patient characteristics are
listed in Table 1, including surgical interventions per-
formed simultaneous to the pump implantation, usually
consisting of a portal vein ligation and/or wedge resections
of adjacent metastases. In addition, these characteristics
were well balanced between the subgroups analyzed.
TABLE 1 Characteristics of 23 patients
Characteristic Value
Age (years)
\60, n (%) 10 (43)






Synchronous disease, n (%)
Yes 19 (83)
No 4 (17)
Bilobar disease, n (%)
Yes 23 (100)
No 0 (0)
Liver-only disease, n (%)
Yes 19 (83)
No 4 (17)
Lung, n (%) 1 (4)
Regional lymph nodes, n (%) 3 (13)
No. of liver metastases, n (%)
B4 4 (17)
[4 19 (83)
Previous systemic chemotherapy, n (%)
Yes 23 (100)
1 regimen 17 (74)
2 regimens 6 (26)
No 0 (0)
Including immunotherapy 8 (35)






Additional hepatic intervention at pump placement, n (%)
No intervention 5 (22)
Portal vein ligation with or without wedge 9 (39)
Wedge resection 7 (31)
Hemihepatectomy with or without wedge 2 (8)
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The patients received FUDR-based HAI for a median of
4 cycles (range, 2–8). In one patient, a pump malfunction
occurred after the first cycle of FUDR, and therefore, he
received intra-arterial bolus 5-fluorouracil instead of FUDR
in the further course. One patient received two courses of
intrahepatic irinotecan (40 mg) in addition to FUDR.
HAI was combined with systemic chemotherapy in 12
patients (52%), while 11 patients (48%) received HAI as a
sole treatment. Concomitant systemic treatment consisted
of a FOLFOX-like regimen (n = 11; 48%), or irinotecan/
oxaliplatin (n = 1; 4%).
Response and Survival
The median OS for all patients was 15.6 months (range,
2.5–55.7 months) (Fig. 1). The median PFS was
3.9 months (range, 0.7–55.7 months), and the median
hepatic PFS was 5.5 months (range, 1.6–55.7 months). No
difference in median OS (hazard ratio [HR] 1.21; 95%
confidence interval [95% CI] 0.48–3.08; P = 0.69) or
hepatic PFS (HR 0.79; 95% CI 0.33–1.91; P = 0.6) was
observed in patients who were treated with FUDR-HAI
alone compared with patients treated with combined
regional and systemic chemotherapy. Nevertheless,
patients receiving a combined treatment showed a trend
toward improved PFS (median 3.4 vs. 5.5 months; HR
0.45; 95% CI 0.18–1.14; P = 0.086). No differences in OS
(HR 1.3; 95% CI 0.51–3.32; P = 0.58), PFS (HR 0.68;
95% CI 0.27–1.72; P = 0.41), or hepatic PFS (HR 1.02;
95% CI 0.42–2.48; P = 0.96) were observed in patients
treated during the early period (years 2000–2004) com-
pared to patients treated during the later period (years
2005–2010). Also, no significant differences in OS (HR
1.5; 95% CI 0.56–4.04; P = 0.41), PFS (HR 2.68; 95% CI
0.94–7.6; P = 0.055) or hepatic PFS (HR 2; 95% CI
0.74–5.41; P = 0.16) were observed in patients who had
previously been treated with one line of systemic chemo-
therapy compared with patients treated with two previous
lines of chemotherapy.
Six (26%) of 23 patients with nonresectable CRLM
showed tumor regression, while 7 patients (30%) had stable
disease. Hence, FUDR-HAI produced an overall response
rate of 26% and a disease control rate of 56%. Hepatic
resection could be performed after HAI in 8 patients (35%)
(Table 2). Surgery was performed after a median of 3
cycles of FUDR-HAI (range, 2–5 cycles). The median OS
in the patients undergoing resection after HAI was 26.1
compared to 12.1 months in the patients who did not
undergo resection (HR 0.4; 95% CI 0.13–1.2; P = 0.09).
The median PFS in the resected patients was 6.7 months
compared to 2.8 months in the unresected patients (HR
0.21; 95% CI 0.07–0.66; P = 0.0034) (Fig. 2). The cor-
responding median hepatic PFS were 6.7 and 3.3 months,
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FIG. 1 Kaplan-Meier analysis of the overall survival (OS) of the
patients after treatment with HAI. Median OS was 15.6 months
(range 2.5–55.7 months)




HAI only, n (%) 11 (48)
HAI plus systemic chemotherapy, n (%) 12 (52)
HAI cycles, median 4
HAI cycles, range 2–8
Response to HAI, n (%)
Complete response 0 (0)
Partial response 6 (26)
Stable disease 7 (30)
Progressive disease 10 (44)
Overall response rate 6 (26)
Disease control rate 13 (56)
Secondary hepatic resection performed, n (%) 8 (35)
Hemihepatectomy with or without wedge 4 (21)
Wedge resection only 4 (8)
Not possible 15 (65)
Resectability assessment (n = 8), n (%)
R0 resection 4/8 (50)
R1 resection 0/8 (0)
R2 resection 4/8 (50)
Additional ablative treatment 4/8 (50)
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Risk Factor Analysis
Extrahepatic disease was the only negative risk factor
for PFS by univariate analysis (liver only vs. extrahepatic
disease: HR 0.03; 95% CI 0.0032–0.28; P \ 0.0001), but
without affecting OS (P = 0.09). The other evaluated
parameters had no statistically significant effect on PFS or
OS (Table 3).
Surgical Complications
Three (13%) complications of less than grade III and
only one (4%) complication of grade III or more (pump
pocket seroma requiring percutaneous drainage, grade IIIa)
occurred after pump implantation.
Liver resection after downsizing HAI was associated
with four complications of grade I or II (50%), and two
complications of grade III or more (25%, one patient with
encephalopathy [grade IVa] and one patient with a biloma
requiring percutaneous drainage [grade IIIa]) were
observed (Table 4).
Adverse Events and Toxicities
Complications and toxicities of grade III or more were
documented in 8 patients (35%) (Table 5). The most fre-
quent adverse events observed during chemotherapy were
diarrhea (n = 4; 17%), infections (n = 3; 13.5%), and
enterocolitis (n = 3; 13.5%). The occurrence of biliary
toxicity grade III or more was observed in 1 patient (4%).
Toxicities of HAI and systemic chemotherapy were man-
ageable by interruption of the treatment or reduction of the
FUDR dose. The pump system could be rescued by anti-
biotic treatment in two documented cases (9%) of pump
infection. The pathogens isolated were Enterobacter clo-
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FIG. 2 a Kaplan-Meier analysis of the overall survival (OS) of the
resected patients compared with the patients not resected after
treatment with hepatic arterial infusion (HAI). Median OS were
26.1 months vs. 12.1 months, respectively (hazard ratio [HR] 0.4;
95% confidence interval [95% CI] 0.13–1.2; P = 0.09). b Kaplan-
Meier analysis of the progression-free survival (PFS) of the resected
patients compared with the patients not resected after treatment with
HAI. Median PFS was 6.7 months vs. 2.8 months, respectively (HR
0.21; 95% CI 0.07–0.66; P = 0.0034)
TABLE 3 Prognostic factors for survival by univariate analysis
Parameter Overall survival Progression-free survival
HR Lower 95% CI Upper 95% CI P value HR Lower 95% CI Upper 95% CI P value
Liver only vs. extrahepatic disease 0.37 0.11 1.22 0.09 0.03 0.003 0.28 0.0000
Age C65 vs. \65 years 0.48 0.13 1.74 0.26 0.39 0.13 1.21 0.09
Colon vs. rectum primary disease 1.48 0.57 3.83 0.42 1.25 0.5 3.14 0.63
Synchronous vs. metachronous disease 0.68 0.22 2.15 0.51 0.42 0.13 1.32 0.13
No. of previous chemotherapy lines 1.5 0.56 4.03 0.41 2.68 0.94 7.59 0.06
C4 lesions vs. \4 lesions 1.41 0.45 4.39 0.56 1.12 0.36 3.44 0.85
Combined treatment vs. HAI alone 1.21 0.48 3.08 0.69 0.45 0.18 1.14 0.09
HR hazard ratio, 95% CI 95% confidence interval, HAI hepatic arterial infusion
1928 P. Samaras et al.
DISCUSSION
This analysis demonstrates efficacy of FUDR-HAI as
second- or third-line treatment in patients with unresectable
CRLM. The median OS was 15.6 months, and the disease
of every third patient became surgically resectable.
Survival benefit associated with HAI correlated with
response rate and resectability of CRLM. The response rate
to regional intra-arterial chemotherapy, applied as second-
or third-line treatment, was 26%. The disease of 8 (35%) of
24 patients with initially unresectable CRLM became
resectable after FUDR-HAI. Resected patients had a sig-
nificantly prolonged PFS (6.7 vs. 2.8 months; P = 0.0034),
while the OS difference did not reach statistical signifi-
cance (26.1 vs. 12.1 months; P = 0.09). This finding is
promising considering the fact that HAI was generally
offered to patients with extensive disease (100% had
bilobar disease, 83% had [4 CRLM) even in the presence
of extrahepatic lymph node metastases or small indeter-
minate pulmonary nodules because other treatment options
were lacking and systemic chemotherapy regimens had
failed. The development of new therapeutic agents greatly
improved the efficacy of chemotherapy in the treatment of
colorectal cancer. Modern regimens achieved response
rates of up to 68% and resection rates of up to 38%.17–20
However, the response rates reported by modern regimens
used as second-line treatment are up to 23%, which is
lower than the response and resectability rates of the
present analysis.31–33
Interestingly, in our series, no further downsizing or
resectability of the tumors could be achieved by the
application of [5 cycles of FUDR-HAI, although in the
literature patients were described as often receiving sub-
stantially more cycles.34,35 Although to our knowledge the
correlation between the number of cycles and treatment
efficacy has never been investigated, it is known that tox-
icity of FUDR, and particularly biliary toxicity, increases
during HAI treatment, requiring dose modifications or
treatment discontinuation.7,36,37
Because HAI prevents intrahepatic tumor progression
but has less influence on extrahepatic disease, it is most
likely that further improvements may be achieved by the
combination of HAI with systemic chemotherapy. Our data
support this assumption: patients receiving regional treat-
ment combined with a FOLFOX-like systemic regimen
showed a trend toward an improved PFS compared with
patients treated with FUDR-HAI alone, but without impact
on OS. The lack of a marked difference of the OS may be
mainly due to the limited patient number analyzed. Hence,
prospective studies with larger patient cohorts have to be
performed to answer this important question. Phase l
clinical trials have defined the appropriate dosage to be
used when combining FUDR-HAI with systemic chemo-
therapy.38,39 So far, no data are available regarding the
impact of monoclonal antibodies such as bevacizumab or
cetuximab/panitumumab added to systemic treatment and
FUDR-HAI. Only a few trials have been published com-
bining FUDR with systemic chemotherapy. Response rates
of 74% have been reported for FUDR-HAI in combination
with systemic irinotecan.28 Of note, the same regimen
yielded only a 43% response rate in patients previously
treated with systemic oxaliplatin.35 The highest efficacy,
with a response rate of 92%, was reported for a combina-
tion of systemic oxaliplatin and irinotecan. The impressive
OS was different for chemotherapy-naive patients
(50 months) compared with previously treated patients
(35 months).40 We have analyzed the impact of the number
of previous treatment lines on patient outcome. Our
patients had received either one or two lines of systemic









Hemorrhage 1 1 II
Urinary tract infection 1 – II
Laryngitis 1 – I








Pump pocket seroma 1 – III
Biliary fistula/biloma – 1 III
Grading according to the Clavien-Dindo classification23
TABLE 5 Adverse events during hepatic arterial infusiona




Pump infection 2 (9) –
Other infection 3 (13.5) –
Diarrhea 3 (13.5) 1 (4.5)
Bile duct stricture/sclerosing cholangitis 1 (4.5) –
Enterocolitis 3 (13.5) –
Fatigue 1 (4.5) 1 (4.5)
Bilirubin elevation 1 (4.5) 1 (4.5)
ASAT elevation 1 (4.5) 1 (4.5)
Alkaline phosphatase elevation 3 (13.5) –
ASAT aspartate aminotransferase
a More than one adverse event per patient is possible
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chemotherapy before FUDR-HAI, with a substantial subset
of patients also having received additional immunotherapy.
No statistically significant differences were seen between
these two patient groups, but as expected, patients with
only one previous line had a tendency for longer PFS.
Our risk factor analysis identified the presence of
extrahepatic disease as the only statistically significant risk
factor for disease progression. This finding confirms the
lack of systemic effect as the main limitation of HAI and
highlights the importance of adequate patient selection. In
our experience, HAI should only be used for a downsizing
strategy in patients without evidence of extrahepatic
disease.
Surgical complications related to the pump placement
are an important aspect of HAI. The most commonly
reported complications are pump pocket hematoma and
seroma (0.3–15%).41,42 Placement of HAI pumps requires
experience. As for all surgical procedures, a learning curve
has been described by Allen et al. in the largest single-
institution experience regarding technical complications of
HAI.41 In our series, only one local complication related to
pump implantation occurred (a fluid collection that could
be resolved by repeated aspiration). All of the other com-
plications were related to the additional surgical procedures
at the liver and were not caused by the pump implantation.
Regarding HAI toxicity, the unique pharmacological
profile of FUDR needs to be considered. FUDR remains
the best drug for selective continuous intra-arterial che-
motherapy because it has a high total body clearance and
first-order kinetics.5 Biliary toxicity is the most relevant
side effect of FUDR, which may be minimized by appro-
priate FUDR dosing, the use of an aggressive dose-
adjustment algorithm, and the addition of dexamethasone
via the hepatic artery.7,28,34 In the present series, only a few
adverse events of grade III or more occurred during intra-
arterial treatment, mainly diarrhea and enterocolitis. They
were all manageable by symptomatic treatment or dose
modifications. Taken together, FUDR-HAI, provided either
alone or combined with systemic chemotherapy, should be
used only in experienced centers as a result of the high
technical and clinical demands of this treatment.
The main limitations of our analysis are its retrospective
nature and the small number of patients. Additionally, our
patients were treated outside of a controlled clinical study
and differed considerably regarding number and duration
of preceding treatments and hepatic interventions per-
formed. However, by carefully analyzing the prospectively
collected data, we were able to distil clinically meaningful
results and shed light on the current value of FUDR-HAI in
patients with colorectal cancer. Similarly, we have
attempted to define the further course of investigation
because randomized prospective trials are not available.
In conclusion, FUDR-HAI shows promising results as a
second- or third-line treatment in patients with nonresec-
table CRLM. Resectability was achieved in one third of the
patients. This was the major factor impacting on survival of
our patients. On the basis of our results, FUDR-HAI in
combination with a FOLFOX-like systemic regimen is an
option for pretreated patients with liver-only disease. The
strategy of combining FUDR-HAI with effective systemic
chemotherapy and immunotherapy in selected patients
should be investigated in further prospective trials.
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